Levetiracetam (LEV) was approved in 1999 by the US Food and Drug Administration (FDA) for the treatment of seizure disorders. It is a second-generation antiepileptic drug (AED) with a unique mechanism – it acts by binding to specific sites on the nerve cell surfaces [1]. It inhibits the burst firing without affecting the normal neuronal excitability, suggesting that it selectively prevents the hyper synchronisation of epileptiform burst firing and propagation of seizure activity [2]. The FDA-labelled indications of LEV include myoclonic seizure, partial seizure, status epilepticus, and tonic-clonic seizures, and off-labelled indications of LEV include prophylactic treatment of migraine, single-drug therapy in partial seizure, and also the treatment of status epilepticus as a second-line agent [2].
ENE